Cargando…
CompLement C5 Antibodies for decreasing brain injury after aneurysmal Subarachnoid Haemorrhage (CLASH): study protocol for a randomised controlled phase II clinical trial
BACKGROUND: The inflammatory response after aneurysmal subarachnoid haemorrhage (aSAH) has been associated with early brain injury, delayed cerebral ischaemia, poor functional outcome, and case fatality. In experimental SAH studies, complement C5 antibodies administered shortly after SAH reduced bra...
Autores principales: | Koopman, Inez, Rinkel, Gabriel J. E., Vergouwen, Mervyn D. I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7687754/ https://www.ncbi.nlm.nih.gov/pubmed/33239044 http://dx.doi.org/10.1186/s13063-020-04838-6 |
Ejemplares similares
-
Aneurysm characteristics and risk of rebleeding after subarachnoid
haemorrhage
por: Koopman, Inez, et al.
Publicado: (2018) -
Devastating delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage
por: Koopman, Inez, et al.
Publicado: (2022) -
Safety and pharmacodynamic efficacy of eculizumab in aneurysmal subarachnoid hemorrhage (CLASH): A phase 2a randomized clinical trial
por: Koopman, Inez, et al.
Publicado: (2023) -
Emergency Medical Management of Aneurysmal Subarachnoid Hemorrhage
por: Vergouwen, Mervyn D. I., et al.
Publicado: (2023) -
Rebleeding After Aneurysmal Subarachnoid Hemorrhage in Two Centers Using Different Blood Pressure Management Strategies
por: Calviere, Lionel, et al.
Publicado: (2022)